GlassScriptPhysician profile
Susannah Mary Stair
NPI 1972595387
$2,890.80
in general payments reported to CMS, 2019-2025
31 companies · $53.71 in 2025
The $53.71 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $190 · 2021: $319 · 2022: $418 · 2023: $417 · 2024: $25.49 · 2025: $53.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.66 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $331.68 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $302.33 | 2019-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $300.41 | 2019-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $286.92 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $244.79 | 2019-2023 | |
| Lilly USA, LLC | $180.88 | 2019-2023 | Mounjaro |
| Abbvie INC. | $143.82 | 2021-2022 | |
| Esperion Therapeutics, INC. | $106.63 | 2021-2023 | Nexletol |
| Amgen INC. | $102.03 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.34 | 2019-2023 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $88.08 | 2021-2023 | Rexulti |
| Alkermes, INC. | $78.46 | 2019-2023 | Vivitrol |
| Exact Sciences Corporation | $73.44 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $72.03 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $60.09 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $51.02 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $41.46 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.11 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $39.90 | 2025 | Darzalex |
| Abbott Laboratories | $37.41 | 2022 | |
| Allergan, INC. | $31.81 | 2020 | |
| Circassia INC. | $31.16 | 2019 | |
| Phathom Pharmaceuticals, INC. | $25.49 | 2024 | Voquezna |
| Eisai INC. | $25.19 | 2019-2021 | |
| Nevro Corp. | $19.67 | 2021 | |
| Scynexis, INC. | $17.42 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.81 | 2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.71 | 2019 | |
| Amarin Pharma, INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susannah Stair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.